KarMMa-2

A Phase 2, Multi-Cohort, Copen-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KARMMA-2)

What's the purpose of the trial?

The goal of this clinical trial is to learn more about the efficacy and safety of bb2121 in patients with relapsed and refractory or high-risk multiple myeloma.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
265
Last Updated
1 week ago
Patient Screener

Participating Centers

There are 13 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Idecabtagene Vicleucel
  • Talquetamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cohort 1b: Relapsed/Refractory Patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.